Efficacy and Safety of Alirocumab 150 mg Every 4 Weeks in Patients With Hypercholesterolemia Not on Statin Therapy: The ODYSSEY CHOICE II Study.
Identifieur interne : 002016 ( Main/Curation ); précédent : 002015; suivant : 002017Efficacy and Safety of Alirocumab 150 mg Every 4 Weeks in Patients With Hypercholesterolemia Not on Statin Therapy: The ODYSSEY CHOICE II Study.
Auteurs : Erik Stroes [Pays-Bas] ; John R. Guyton [États-Unis] ; Norman Lepor [États-Unis] ; Fernando Civeira [Espagne] ; Daniel Gaudet [Canada] ; Gerald F. Watts [Australie] ; Marie T. Baccara-Dinet [France] ; Guillaume Lecorps [France] ; Garen Manvelian [États-Unis] ; Michel Farnier [France]Source :
- Journal of the American Heart Association [ 2047-9980 ] ; 2016.
Abstract
The PCSK9 antibody alirocumab (75 mg every 2 weeks; Q2W) as monotherapy reduced low-density lipoprotein-cholesterol (LDL-C) levels by 47%. Because the option of a monthly dosing regimen is convenient, ODYSSEY CHOICE II evaluated alirocumab 150 mg Q4W in patients with inadequately controlled hypercholesterolemia and not on statin (majority with statin-associated muscle symptoms), receiving treatment with fenofibrate, ezetimibe, or diet alone.
DOI: 10.1161/JAHA.116.003421
PubMed: 27625344
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001945
- to stream PubMed, to step Curation: Pour aller vers cette notice dans l'étape Curation :001921
- to stream PubMed, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :001921
- to stream Ncbi, to step Merge: Pour aller vers cette notice dans l'étape Curation :003B40
- to stream Ncbi, to step Curation: Pour aller vers cette notice dans l'étape Curation :003B40
- to stream Ncbi, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :003B40
- to stream Main, to step Merge: Pour aller vers cette notice dans l'étape Curation :002015
Links to Exploration step
pubmed:27625344Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Efficacy and Safety of Alirocumab 150 mg Every 4 Weeks in Patients With Hypercholesterolemia Not on Statin Therapy: The ODYSSEY CHOICE II Study.</title>
<author><name sortKey="Stroes, Erik" sort="Stroes, Erik" uniqKey="Stroes E" first="Erik" last="Stroes">Erik Stroes</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands e.s.stroes@amc.uva.nl.</nlm:affiliation>
<country wicri:rule="url">Pays-Bas</country>
<wicri:regionArea>Department of Vascular Medicine, Academic Medical Center, Amsterdam</wicri:regionArea>
<placeName><settlement type="city">Amsterdam</settlement>
<region nuts="2" type="province">Hollande-Septentrionale</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Guyton, John R" sort="Guyton, John R" uniqKey="Guyton J" first="John R" last="Guyton">John R. Guyton</name>
<affiliation wicri:level="2"><nlm:affiliation>Duke University Medical Center, Durham, NC.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Caroline du Nord</region>
</placeName>
<wicri:cityArea>Duke University Medical Center, Durham</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Lepor, Norman" sort="Lepor, Norman" uniqKey="Lepor N" first="Norman" last="Lepor">Norman Lepor</name>
<affiliation wicri:level="2"><nlm:affiliation>Westside Medical Associates of Los Angeles Cedars-Sinai Heart Institute, Beverly Hills, CA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Californie</region>
</placeName>
<wicri:cityArea>Westside Medical Associates of Los Angeles Cedars-Sinai Heart Institute, Beverly Hills</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Civeira, Fernando" sort="Civeira, Fernando" uniqKey="Civeira F" first="Fernando" last="Civeira">Fernando Civeira</name>
<affiliation wicri:level="1"><nlm:affiliation>Lipid Unit, Hospital Universitario Miguel Servet, IIS Aragon, Zaragoza, Spain.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Lipid Unit, Hospital Universitario Miguel Servet, IIS Aragon, Zaragoza</wicri:regionArea>
<wicri:noRegion>Zaragoza</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Gaudet, Daniel" sort="Gaudet, Daniel" uniqKey="Gaudet D" first="Daniel" last="Gaudet">Daniel Gaudet</name>
<affiliation wicri:level="1"><nlm:affiliation>ECOGENE-21 Clinical and Translational Research Center and Department of Medicine, Université de Montréal, Chicoutimi, Quebec, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>ECOGENE-21 Clinical and Translational Research Center and Department of Medicine, Université de Montréal, Chicoutimi, Quebec</wicri:regionArea>
<wicri:noRegion>Quebec</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Watts, Gerald F" sort="Watts, Gerald F" uniqKey="Watts G" first="Gerald F" last="Watts">Gerald F. Watts</name>
<affiliation wicri:level="1"><nlm:affiliation>Lipid Disorders Clinic, Cardiovascular Medicine, Royal Perth Hospital, School of Medicine and Pharmacology, University of Western Australia, Perth, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Lipid Disorders Clinic, Cardiovascular Medicine, Royal Perth Hospital, School of Medicine and Pharmacology, University of Western Australia, Perth</wicri:regionArea>
<wicri:noRegion>Perth</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Baccara Dinet, Marie T" sort="Baccara Dinet, Marie T" uniqKey="Baccara Dinet M" first="Marie T" last="Baccara-Dinet">Marie T. Baccara-Dinet</name>
<affiliation wicri:level="3"><nlm:affiliation>Sanofi, Clinical Development, R&D, Montpellier, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Sanofi, Clinical Development, R&D, Montpellier</wicri:regionArea>
<placeName><region type="region">Occitanie (région administrative)</region>
<region type="old region">Languedoc-Roussillon</region>
<settlement type="city">Montpellier</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Lecorps, Guillaume" sort="Lecorps, Guillaume" uniqKey="Lecorps G" first="Guillaume" last="Lecorps">Guillaume Lecorps</name>
<affiliation wicri:level="1"><nlm:affiliation>Sanofi, Chilly-Mazarin, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Sanofi, Chilly-Mazarin</wicri:regionArea>
<wicri:noRegion>Chilly-Mazarin</wicri:noRegion>
<wicri:noRegion>Chilly-Mazarin</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Manvelian, Garen" sort="Manvelian, Garen" uniqKey="Manvelian G" first="Garen" last="Manvelian">Garen Manvelian</name>
<affiliation wicri:level="2"><nlm:affiliation>Regeneron Pharmaceuticals Inc, Tarrytown, NY.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">État de New York</region>
</placeName>
<wicri:cityArea>Regeneron Pharmaceuticals Inc, Tarrytown</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Farnier, Michel" sort="Farnier, Michel" uniqKey="Farnier M" first="Michel" last="Farnier">Michel Farnier</name>
<affiliation wicri:level="3"><nlm:affiliation>Lipid Clinic, Point Médical, Dijon, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Lipid Clinic, Point Médical, Dijon</wicri:regionArea>
<placeName><region type="region">Bourgogne-Franche-Comté</region>
<region type="old region">Bourgogne</region>
<settlement type="city">Dijon</settlement>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2016">2016</date>
<idno type="RBID">pubmed:27625344</idno>
<idno type="pmid">27625344</idno>
<idno type="doi">10.1161/JAHA.116.003421</idno>
<idno type="wicri:Area/PubMed/Corpus">001945</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001945</idno>
<idno type="wicri:Area/PubMed/Curation">001921</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001921</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001921</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001921</idno>
<idno type="wicri:Area/Ncbi/Merge">003B40</idno>
<idno type="wicri:Area/Ncbi/Curation">003B40</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">003B40</idno>
<idno type="wicri:Area/Main/Merge">002015</idno>
<idno type="wicri:Area/Main/Curation">002016</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Efficacy and Safety of Alirocumab 150 mg Every 4 Weeks in Patients With Hypercholesterolemia Not on Statin Therapy: The ODYSSEY CHOICE II Study.</title>
<author><name sortKey="Stroes, Erik" sort="Stroes, Erik" uniqKey="Stroes E" first="Erik" last="Stroes">Erik Stroes</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands e.s.stroes@amc.uva.nl.</nlm:affiliation>
<country wicri:rule="url">Pays-Bas</country>
<wicri:regionArea>Department of Vascular Medicine, Academic Medical Center, Amsterdam</wicri:regionArea>
<placeName><settlement type="city">Amsterdam</settlement>
<region nuts="2" type="province">Hollande-Septentrionale</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Guyton, John R" sort="Guyton, John R" uniqKey="Guyton J" first="John R" last="Guyton">John R. Guyton</name>
<affiliation wicri:level="2"><nlm:affiliation>Duke University Medical Center, Durham, NC.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Caroline du Nord</region>
</placeName>
<wicri:cityArea>Duke University Medical Center, Durham</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Lepor, Norman" sort="Lepor, Norman" uniqKey="Lepor N" first="Norman" last="Lepor">Norman Lepor</name>
<affiliation wicri:level="2"><nlm:affiliation>Westside Medical Associates of Los Angeles Cedars-Sinai Heart Institute, Beverly Hills, CA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Californie</region>
</placeName>
<wicri:cityArea>Westside Medical Associates of Los Angeles Cedars-Sinai Heart Institute, Beverly Hills</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Civeira, Fernando" sort="Civeira, Fernando" uniqKey="Civeira F" first="Fernando" last="Civeira">Fernando Civeira</name>
<affiliation wicri:level="1"><nlm:affiliation>Lipid Unit, Hospital Universitario Miguel Servet, IIS Aragon, Zaragoza, Spain.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Lipid Unit, Hospital Universitario Miguel Servet, IIS Aragon, Zaragoza</wicri:regionArea>
<wicri:noRegion>Zaragoza</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Gaudet, Daniel" sort="Gaudet, Daniel" uniqKey="Gaudet D" first="Daniel" last="Gaudet">Daniel Gaudet</name>
<affiliation wicri:level="1"><nlm:affiliation>ECOGENE-21 Clinical and Translational Research Center and Department of Medicine, Université de Montréal, Chicoutimi, Quebec, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>ECOGENE-21 Clinical and Translational Research Center and Department of Medicine, Université de Montréal, Chicoutimi, Quebec</wicri:regionArea>
<wicri:noRegion>Quebec</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Watts, Gerald F" sort="Watts, Gerald F" uniqKey="Watts G" first="Gerald F" last="Watts">Gerald F. Watts</name>
<affiliation wicri:level="1"><nlm:affiliation>Lipid Disorders Clinic, Cardiovascular Medicine, Royal Perth Hospital, School of Medicine and Pharmacology, University of Western Australia, Perth, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Lipid Disorders Clinic, Cardiovascular Medicine, Royal Perth Hospital, School of Medicine and Pharmacology, University of Western Australia, Perth</wicri:regionArea>
<wicri:noRegion>Perth</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Baccara Dinet, Marie T" sort="Baccara Dinet, Marie T" uniqKey="Baccara Dinet M" first="Marie T" last="Baccara-Dinet">Marie T. Baccara-Dinet</name>
<affiliation wicri:level="3"><nlm:affiliation>Sanofi, Clinical Development, R&D, Montpellier, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Sanofi, Clinical Development, R&D, Montpellier</wicri:regionArea>
<placeName><region type="region">Occitanie (région administrative)</region>
<region type="old region">Languedoc-Roussillon</region>
<settlement type="city">Montpellier</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Lecorps, Guillaume" sort="Lecorps, Guillaume" uniqKey="Lecorps G" first="Guillaume" last="Lecorps">Guillaume Lecorps</name>
<affiliation wicri:level="1"><nlm:affiliation>Sanofi, Chilly-Mazarin, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Sanofi, Chilly-Mazarin</wicri:regionArea>
<wicri:noRegion>Chilly-Mazarin</wicri:noRegion>
<wicri:noRegion>Chilly-Mazarin</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Manvelian, Garen" sort="Manvelian, Garen" uniqKey="Manvelian G" first="Garen" last="Manvelian">Garen Manvelian</name>
<affiliation wicri:level="2"><nlm:affiliation>Regeneron Pharmaceuticals Inc, Tarrytown, NY.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">État de New York</region>
</placeName>
<wicri:cityArea>Regeneron Pharmaceuticals Inc, Tarrytown</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Farnier, Michel" sort="Farnier, Michel" uniqKey="Farnier M" first="Michel" last="Farnier">Michel Farnier</name>
<affiliation wicri:level="3"><nlm:affiliation>Lipid Clinic, Point Médical, Dijon, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Lipid Clinic, Point Médical, Dijon</wicri:regionArea>
<placeName><region type="region">Bourgogne-Franche-Comté</region>
<region type="old region">Bourgogne</region>
<settlement type="city">Dijon</settlement>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j">Journal of the American Heart Association</title>
<idno type="eISSN">2047-9980</idno>
<imprint><date when="2016" type="published">2016</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The PCSK9 antibody alirocumab (75 mg every 2 weeks; Q2W) as monotherapy reduced low-density lipoprotein-cholesterol (LDL-C) levels by 47%. Because the option of a monthly dosing regimen is convenient, ODYSSEY CHOICE II evaluated alirocumab 150 mg Q4W in patients with inadequately controlled hypercholesterolemia and not on statin (majority with statin-associated muscle symptoms), receiving treatment with fenofibrate, ezetimibe, or diet alone.</div>
</front>
</TEI>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002016 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Curation/biblio.hfd -nk 002016 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Asie |area= AustralieFrV1 |flux= Main |étape= Curation |type= RBID |clé= pubmed:27625344 |texte= Efficacy and Safety of Alirocumab 150 mg Every 4 Weeks in Patients With Hypercholesterolemia Not on Statin Therapy: The ODYSSEY CHOICE II Study. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Curation/RBID.i -Sk "pubmed:27625344" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Curation/biblio.hfd \ | NlmPubMed2Wicri -a AustralieFrV1
This area was generated with Dilib version V0.6.33. |